Introduction
Bovine herpesvirus-1 (BHV-1) infection, which causes infectious bovine rhinotracheitis (IBR) and infectious pustular vulvovaginitis (Gibbs & Rweyemamu, 1977) , is widely controlled by vaccination with live attenuated or inactivated vaccines. Since currently used vaccines did not allow serological differentiation between BHV-1-vaccinated and BHV-1-infected cattle, marker vaccines have been developed in which the gE gene has been deleted . The gEnegative mutants of BHV-1 are highly attenuated in calves and induce protective immunity against disease after challenge Author for correspondence : Geraldine Taylor.
Fax j44 1635 577263. e-mail Geraldine. Taylor!bbsrc.ac.uk for calves. Vaccination with BHV-1/G induced BRSVspecific antibody in serum and respiratory secretions. However, only one calf developed low levels of BRSV complement-dependent neutralizing antibody. Although BHV-1/G primed calves for BRSVspecific lymphocyte proliferative responses, there was no evidence for priming of BRSV-specific cytotoxic T cells. After challenge with BRSV, there was a significant reduction in nasopharyngeal excretion of BRSV in BHV-1/G-vaccinated calves compared with controls and BRSV was isolated from the lung of only one of five vaccinated calves compared with all four control animals. In addition, the extent of gross pneumonic lesions 7 days after BRSV challenge was significantly reduced in calves vaccinated with BHV-1/G compared with controls given BHV-1/gEfs. with virulent BHV-1 strains. Such mutants of BHV-1 would also be of value as viral vectors to vaccinate against other bovine respiratory pathogens.
Bovine respiratory syncytial virus (BRSV) is a major cause of lower respiratory tract disease in young calves (Stott et al., 1980) . Studies in a number of animal models of human (H)RSV infection have established the importance of the fusion (F) and attachment (G) surface glycoproteins in conferring protection against infection with HRSV (Olmsted et al., 1986 (Olmsted et al., , 1988 Stott et al., 1987 ; Wertz et al., 1987) . In addition, recombinant vaccinia viruses (rVV) expressing the F, G or nucleo-(N) proteins of BRSV protect calves against infection with BRSV ( Taylor et al., 1997) . These studies with rVV in calves suggest that although scarification with rVV expressing either the F or N proteins reduces nasopharyngeal excretion of BRSV, scarification of calves with rVV expressing the G protein only reduces pulmonary BRSV infection. There is evidence that induction of resistance to infection, in both the upper and lower respiratory tract, by recombinant viral vectors may be best achieved by infection of the respiratory mucosa with the recombinant virus (Takao et al., 1997) . Since replication of rVV in the bovine respiratory tract appeared to be limited after intratracheal inoculation (Taylor et al., 1997) , a more suitable viral vector may be one that replicates well in the bovine respiratory tract, such as BHV-1.
Initial attempts to use BHV-1 for expression of the F and G proteins of BRSV were unsuccessful due to instability of the RNAs in the nucleus of infected cells (Kuhnle et al., 1998) . In order to determine if expression of these glycoproteins could be achieved using a modified open reading frame (ORF), in which BHV-1 gD codon-usage preferences were applied and in which putative splice signals were avoided, a chemically synthesized G ORF was constructed (Kuhnle et al., 1998) . Since the G protein mRNA of the 391-2 strain of BRSV is only 838 nucleotides in length whereas the F protein mRNA is 1899 nucleotides (Lerch et al., 1990 (Lerch et al., , 1991 , the G protein was chosen for these studies because of the comparative ease of construction of a synthetic ORF encoding this protein compared with one encoding the F protein. The resulting G protein produced by recombinant BHV-1 was identical to the G protein produced by BRSV (Kuhnle et al., 1998) . In the present study, we examined the ability of a recombinant BHV-1, which contained the synthetic G ORF inserted behind the gE promoter of BHV-1, to induce resistance to BRSV infection in both the upper and lower respiratory tract of the calf.
Methods
Viruses and cells. The parent strain of the BHV-1 recombinant viruses used in this study is the Dutch BHV-1 strain Lam. This strain was isolated in the Netherlands during an IBR outbreak in 1972 and has the BHV-1.1 or ' IBR-like ' genotype. The BHV-1 viruses were propagated and titrated on embryonic bovine trachea (Ebtr) cells grown in Earle's minimal essential medium (EMEM) with 10 % foetal calf serum and antibiotics (12 U penicillin, 125 µg streptomycin, 37n5 U nystatin and 37n5 µg kanamycin per ml). Virus was titrated in microtitre plates of Ebtr cells and after 5 days, the cells were examined microscopically for typical BHV-1 cytopathic effect. Titres were calculated according to the Reed-Muench method and expressed as log "! 50 % tissue culture infectious doses (TCID &! ) per ml. The Snook strain of BRSV (Thomas et al., 1982) was isolated from a calf with pneumonia and has been passaged twice in calf testis cells and three times in calf kidney (CK) cells. Stocks of virus for inoculation of calves were prepared in primary CK cells and stored in liquid nitrogen. Virus stocks were free from bovine viral diarrhoea virus and mycoplasmas. Titres of BRSV in samples from calves were determined by plaque assay on secondary CK cells as described previously .
Construction of recombinant BHV-1 expressing the G protein of BRSV (BHV/G). A synthetic gene that encodes the ORF of the G gene of BRSV (Kuhnle et al., 1998) was recombined into a BHV-1 vector. To this end the BRSV G gene was first cloned into a BHV-1 recombination cassette for the glycoprotein E (gE) locus. This cassette consists of two genome fragments of BHV-1 strain Lam that border the gE gene (Fig. 1 a) . The upstream fragment starts at the PstI site in the neighbouring glycoprotein I (gI) gene and ends at the AsuII site, 17 nucleotides in front of the start codon of the gE ORF. The downstream fragment starts at the EcoNI site at the stop codon of the gE ORF and ends at the first SmaI site downstream of the gE ORF in the terminal repeat of BHV-1. Both fragments were cloned in the original orientation in pUC18 and the resulting cassette was named p175. These and all other cloning experiments were performed according to standard procedures (Sambrook et al., 1989) . The BRSV G gene was cloned between the AsuII and EcoNI sites of p175 in the proper orientation to allow the gE promoter to control transcription of the inserted gene and the resulting construct was named p531 (Fig. 1) . To recombine the BRSV G gene into the genome of BHV-1, the cassette was linearized using restriction endonuclease PstI and cotransfected with genomic DNA of BHV-1 as described previously (Van Engelenburg et al., 1994) . Recombinants encoding the BRSV G gene were selected by limiting dilution on microtitre plates using an immunoperoxidase monolayer assay (IPMA) with monoclonal antibody (MAb) 20, specific for the cysteine-rich region of the G protein of BRSV (Langedijk et al., 1996) . The IPMA was performed according to the method described by Kramps et al. (1994) using 3-amino-9-ethylcarbazole (Sigma) as a substrate. The selected recombinant was plaque purified three times and its DNA analysed to check whether only the intended recombination had taken place (data not shown). The resulting recombinant BHV-1\G was named 531. Expression of the G protein was confirmed by immunoperoxidase staining of BHV-BHGA 1\G-infected Ebtr cell monolayers using MAbs specific for the G protein of BRSV.
Construction of the BHV-1 gE frame-shift mutant (BHV-1/gEfs). A gE-negative mutant BHV-1 was used as a control for the BHV-1\G recombinant. To avoid the possible disadvantages of a large deletion in the BHV-1 genome, a gE frame-shift mutant was preferred above a gE-deletion mutant. To construct the BHV-1 gE frame-shift mutant, a 1n8 kb PstI fragment that harbours a large part of the BHV-1 gI gene and the N-terminal end of the BHV-1 gE gene was used. This PstI fragment contains a unique recognition site for restriction enzyme Tth111I, which cuts in the gE ORF 124 bp downstream of the gE start codon. Tth111I creates sticky ends in which one 5h nucleotide is protruding. The created ends were filled in using Klenow large fragment DNA polymerase in the presence of dCTP and dGTP. The resulting blunt ends were religated creating a molecule with a 2 bp insertion in the gE ORF. This insertion introduces a frame-shift in the coding region starting at amino acid 41 of the gE ORF and amino acid 16 of the putative, mature gE protein. This frame-shift mutation was recombined into the genome of BHV-1. The stability of this mutation has been tested both in vitro (data not shown) and in vivo and no revertants have been found.
Animals and experimental design. Gnotobiotic, BRSV-seronegative calves were derived by hysterotomy, reared on a milk-based diet as described previously (Dennis et al., 1976 ; Hoare et al., 1976) and maintained individually in plastic isolators. The calves were shown to be free of bovine viral diarrhoea virus. Calves, aged 12 to 27 days (mean 20p3n4 days) were inoculated with 10( TCID &! of BHV-1\G in a volume of 20 ml, of which 10 ml was administered intranasally (i.n.) and 10 ml intratracheally (i.t.). As controls, calves were inoculated i.n. and i.t. with 10( TCID &! of BHV-1\gEfs. Ten calves were randomly allocated to two groups and data were accumulated from a series of experiments which involved two or four calves at a time, of which half were vaccinated with BHV-1\G and half with BHV-1\gEfs. Nasal swabs were taken daily to monitor BHV-1 excretion. Lung wash (LW) samples, obtained by instilling approximately 100 ml phosphate-buffered saline (PBSa) into the lungs via 3 mm portex tubing, were collected 0, 2, 6 and 10 days after BHV-1 infection to monitor BHV-1 replication in the lung. Samples collected from the nasal passages and lungs of calves were stored at k70 mC prior to virus titration. Calves were examined daily for clinical signs of disease. A clinical score of one was allocated for each of the following parameters : a 1 mC or more rise in body temperature above pre-inoculation temperature ; dull or apathetic demeanour ; a respiratory rate 10 respirations per minute above pre-inoculation rates ; inappetance and recumbency. Thus, the maximum possible score each day was 5. Serum samples were taken at 3-weekly intervals and nasal wash (NW) and LW samples for antibody detection were obtained immediately prior to vaccination and at the time of BRSV challenge. NW samples were collected by infusing 50 ml PBSa into the nares of the standing animal and collecting the eluant, three times.
Calves were challenged 6 weeks after vaccination with 10& p.f.u. of BRSV in a volume of 20 ml, 10 ml administered by the i.n. route and 10 ml by the i.t. route. Nasopharyngeal swabs were taken daily following challenge to monitor BRSV excretion. Calves were killed 7 days after challenge by intravenous pentobarbitone Na. Following slaughter, lungs were excised, macroscopic lesions recorded on a standard lung diagram and expressed as % pneumonic consolidation. Three lobes were clamped off (usually right apical, right cardiac and left cardiac lobes) and a tracheobronchial lung wash (TBLW) made with 200 to 300 ml PBSa. The TBLW was centrifuged at 300 g for 15 min and the cells resuspended in 5 ml lung buffer (Taylor et al., 1984 b) for virus isolation ; a sample of the supernatant was retained for antibody analysis. The clamped lobes were excised and representative portions taken for virology and histology. Three pieces of pneumonic lung, taken from different lobes, were homogenized in lung buffer to give a 20 % (w\v) suspension. Homogenates were centrifuged at 9000 g for 1 min and the supernatant assayed for virus. Samples from the nasopharynx and lungs were stored at k70 mC prior to virus isolation.
Serology. Antibody responses to BRSV and to BHV-1 were determined by ELISA (Taylor et al., 1995) . The BRSV antigen was composed of detergent-treated CK cells infected with the Snook strain of BRSV. Using this antigen, the titre of a MAb specific for the G protein of BRSV was greater than log "! 6n5. Sham-infected cells treated in the same way were used as control antigen. The BHV-1 antigen was composed of detergent-treated Ebtr cells infected with BHV-1\gEfs ; sham-infected cells treated in the same way were used as control antigen. Isotypespecific antibody responses to BRSV were examined by ELISA as described previously (Taylor et al., 1995) . Neutralizing antibodies to BRSV were detected by a plaque reduction assay on secondary CK cells as described previously, with and without rabbit complement (Kennedy et al., 1992) .
Lymphocyte proliferation assay. Peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood as described previously (Taylor et al., 1995) and restimulated with BRSV antigen prepared from frozen and thawed CK cells infected with the Snook strain of BRSV . Lysates from uninfected CK cells were used as control antigens. After 5 days incubation, cultures were labelled with 1 µCi [methyl-$H]thymidine per well, incubated for a further 18 h and harvested as described previously . All assays were performed in triplicate. Because c.p.m. in cultures incubated with control antigen ranged from 390 to 70 000 c.p.m., the lymphocyte proliferative responses were expressed as the ratio of c.p.m. in cultures stimulated with BRSV antigen to that in cultures stimulated with control antigen and expressed as the stimulation index (S.I.). An S.I. greater than 3 was considered to be a significant response. Cytotoxicity assay. Testicular or skin fibroblasts (10') were infected with the 391-2 strain of BRSV, labelled with &"Cr and used in a cytotoxicity assay as described previously (Gaddum et al., 1996) . MHC serotyping of PBMC was carried out as described previously (Van Lierop et al., 1995) and the BoLA types were defined according to the Fifth International BoLA workshop (Davies et al., 1994) . BRSV-infected and uninfected autologous and MHC-mismatched cells were used as targets, and PBMC and pulmonary lymphocytes, prepared by enzymatic digestion of lung tissue as described elsewhere (Gaddum et al., 1996) , were used as effector cells. The % specific release was calculated as 100i(c.p.m. in testkc.p.m. in spontaneous release)\(c.p.m. in total releasekc.p.m. in spontaneous release) using the mean value of triplicate wells, provided that the standard deviation of the individual values did not exceed 20 % of the mean value. Spontaneous and total release were determined from wells containing target cells and 100 µl of medium or 1 % SDS, respectively.
Histology. Tissue for histology was fixed in mercuric formalin (10 % formaldehyde and 90 % saturated mercuric chloride solution), paraffin wax embedded and stained with haematoxylin and eosin (H&E) or phloxinetartrazine.
Results

Expression of the G protein of BRSV increased the virulence of BHV-1 for calves
Clinical signs in the 14 day period following vaccination were mild in all calves, except for one calf vaccinated with BHGB G. Taylor and others G. Taylor and others BHV-1\G, but were significantly greater in calves infected with BHV-1\G than in those infected with BHV-1\gEfs (Fig.  2 c) (P 0n05). One calf vaccinated with BHV-1\G was in sternal recumbency for 24 h, 5 days after vaccination and required supportive therapy. The calf recovered and was feeding normally after 2 days. Rectal temperatures in two of five control calves showed a transient rise compared with three of five calves vaccinated with BHV-1\G. Only one control calf was scored as apathetic on one day compared with all five BHV-1\G-vaccinated calves, two for longer than a day and three of which were also inappetant. Respiratory rates were raised in three of five BHV-1\G-vaccinated calves (50-60 respirations\min), but not in the calves vaccinated with BHV1\gEfs. All calves, except one control calf, showed a marked increase in cells and cellular debris in the LW taken on day 6 and day 10 post-vaccination compared with the initial samples taken on day 0 and day 2.
Following i.n. and i.t. inoculation of calves, BHV-1\G and BHV-1\gEfs were isolated in similar titres from the nasal passages (Fig. 2 a) . Virus was first isolated one day after infection and continued to be excreted from the nose until days 10 to 13. BHV-1 was isolated from LW 2 and 6 days after infection and was undetectable by day 10 (Fig. 2 b) . Titres of BHV-1\G in LW were significantly greater than those of BHV1\gEfs (P 0n02).
Antibody responses induced by vaccination
The serum ELISA antibody responses to BHV-1 were similar in both groups of calves vaccinated with BHV-1 recombinants and antibody titres reached a plateau 3 weeks after vaccination (Fig. 3) . BRSV-specific ELISA antibody was only detected in calves vaccinated with BHV-1\G and titres were approximately 40-fold lower than those to BHV-1 (Fig.  3) . Seven days after BRSV challenge (week 7), serum antibody to BRSV increased approximately 4-fold. Only one calf (31-96) developed serum neutralizing antibody (titre l 1 : 14), which was detected only in the presence of rabbit complement. After BRSV challenge, neutralizing antibodies were detectable in two calves (31-96 and 1-96) at titres of 1 : 13 and 1 : 40, respectively.
Following vaccination with BHV-1\G, IgM, IgG1 and IgG2 antibodies to BRSV were detected in sera, with IgG1 being the predominant isotype (Fig. 4 a) . Seven days after BRSV challenge, there was an increase in IgM, IgG1 and IgG2 serum antibodies. Whereas little or no IgA antibody to BRSV was detectable in sera, low levels of IgA antibody were detected in LW 6 weeks after vaccination ; the titres increased approximately 4-fold 7 days after BRSV challenge (Fig. 4 b) . Low levels of IgM and IgG1 antibody were also detected in LW 7 days after BRSV challenge. BRSV-specific antibody was only detected in NW after BRSV challenge and consisted of BHGC BHV-1/BRSV G protein recombinant in calves BHV-1/BRSV G protein recombinant in calves IgM, IgG1 and IgA, with the predominant antibody being IgM (Fig. 4 b) . BRSV-specific antibody was not detected in sera, LW or NW samples of any of the control calves.
RSV-specific T cell responses
Following vaccination with BHV-1\G, transient BRSVspecific lymphocyte proliferative responses were detected in three of five calves (Fig. 5) . Seven days after BRSV challenge, RSV-specific proliferative responses were detected in all five BHV-1\G-vaccinated calves but not in any of the control calves vaccinated with BHV-1\gEfs.
In order to determine if vaccination with BHV-1\G induced a primary BRSV-specific cytotoxic T lymphocyte (CTL) response, PBMC, taken 7 to 10 days after vaccination, were examined for their ability to lyse BRSV-infected, autologous target cells and BRSV-infected, MHC-mismatched target cells. There was no evidence for the induction of a primary BRSVspecific CTL response following vaccination with BHV-1\G (results not shown). PBMC and pulmonary lymphocytes, obtained 7 days after BRSV challenge, were also examined for their ability to lyse BRSV-infected cells. Low levels of MHCrestricted lysis of BRSV-infected cells by PBMC were detected in three of five calves vaccinated with BHV-1\G and a high level of MHC-restricted lysis of BRSV-infected cells was detected in one of the control calves (Fig. 6 ). There was no detectable lysis of BRSV-infected cells by pulmonary lymphocytes from any of the calves.
Vaccination with BHV-1/G induces resistance to BRSV infection
Clinical signs were not observed in the 7 day period following challenge with BRSV except in one BHV-1\G-vaccinated calf. Signs in this calf comprised intermittent inappetance and dullness accompanied by a marked increase in salivation and rumination. The signs were considered to be related to a partial obstruction with a foreign body in the lower oesophagus.
Following BRSV challenge, there was a significant reduction in BRSV infection in both the upper and lower respiratory tract of calves vaccinated with BHV-1\G when compared with G. Taylor and others G. Taylor and others 1 n 6 p 0 n 9 a 1 n 3 p 0 n 2 b (2\15) 1n8p3n0 c * Significant reduction in virus titre compared with controls (Mann-Whitney U-test) at P 0n02 (a), P 0n0001 (b) and P 0n05 (c). † No. of lung samples infected\total examined.
controls. Thus, although BRSV was isolated from the nasopharynx of four of five BHV-1\G-vaccinated calves and all of the control calves vaccinated with BHV-1\gEfs, there was a significant reduction in the amount of BRSV excreted from the nasopharynx of BHV-1\G-vaccinated calves compared with control animals (P 0n05) (Fig. 7) . In addition, there was a significant reduction in the titre of BRSV isolated from the TBLW of BHV-1\G-vaccinated calves when compared with controls (P 0n02) ( Table 1) . Three different areas of lung from each calf were homogenized for isolation of BRSV and virus was isolated from only two lung samples from one calf immunized with BHV-1\G compared with all lung samples from all calves vaccinated with BHV-1\gEfs (Table 1) . After challenge with BRSV, the mean pneumonic consolidation score for control calves was significantly greater than that of BHV-1\G-vaccinated calves (P 0n05) ( Table 1) .
The pneumonic consolidation scores of four of the BHV-1\G-vaccinated animals were all 1 %, whereas the lesion score of the other BHV-1\G-vaccinated calf, which had an unrelated illness following BRSV challenge, was 7. Histologically, the pneumonia in this animal was an atypical muco-exudative bronchiolitis, probably induced by the presence of a foreign body in the lower oesophagus. In contrast, the pneumonic lesion seen to a greater or lesser extent in the control calves was a non-suppurative, proliferative bronchiolitis typical of experimental BRSV infection. Typical features were hypertrophy and desquamation of the bronchiolar and alveolar epithelium with syncytial formation, peribronchiolar and alveolar lymphoid infiltration, obstruction of small bronchioles with the non-suppurative exudate and patchy collapse and consolidation of lung parenchyma. Mild and restricted histological evidence of typical BRSV bronchiolitis was also recognized in one BHV-1\G-vaccinated calf. All five BHV-1\G-vaccinated calves showed a degree of peribronchiolar or perivascular lymphoreticular hyperplasia with alveolar lymphoid infiltration, which was not seen in control animals. As indicated above, the typical inflammatory response was essentially a non-suppurative one and neutrophilic and eosinophilic granulocytes were seen only occasionally.
Discussion
Infection of the upper and lower respiratory tract with a recombinant BHV-1 expressing the G protein of BRSV induced significant resistance to BRSV infection in calves. Even though BHV-1\G grew to higher titres in the upper respiratory tract than in the lungs, the level of protection against BRSV infection was greater in the lung than in the nasopharynx. Thus, BRSV was isolated from the nasopharynx of four of five calves vaccinated with BHV-1\G, but from the lung tissue of only one of five animals. Although, the level of protection against nasopharyngeal infection with BRSV was greater in calves vaccinated i.n. and i.t. with BHV-1\G than in those scarified with rVV-G (Taylor et al., 1997) , it was not as great as that induced in calves infected 6 weeks previously with BRSV (G. Taylor and others, unpublished observations) .
Protection against HRSV infection induced in mice by rVV-G appears to be mediated by antibody (Connors et al., 1992) ; however, the serum antibody response to BRSV induced by BHV-1\G was poor in comparison with that to BHV-1. Only one calf developed complement-dependent neutralizing antibody to BRSV after vaccination and this was the only BHV-1\G-vaccinated calf that was infected with BRSV in the lung following challenge. Similarly, only low levels of complementdependent neutralizing antibodies were induced by rVV-G in calves (Taylor et al., 1997) . Since non-neutralizing MAbs to the G protein can protect against HRSV infection in mice , it may be that antibodies to the G protein mediate protection by mechanisms other than virus neutralization. Although there was little or no antibody detected in BHGE either the lung or nose of BHV-1\G-vaccinated calves at the time of BRSV challenge, there was a rapid IgM, IgG1 and IgA RSV-specific antibody response 7 days after challenge and it is possible that protection induced by BHV-1\G was mediated by locally produced antibody. The appearance of IgA antibody in the lung of BHV-1\G-vaccinated calves 7 days after BRSV challenge contrasts with the failure to detect IgA antibody in the lungs of calves scarified with rVV-G and challenged with BRSV (Taylor et al., 1997) .
There was no evidence for priming of BRSV-specific CTLs by BHV-1\G and the appearance of CTLs in the peripheral blood of BHV-1\G-vaccinated calves after challenge with BRSV was similar to that in control calves and similar to that reported previously after a primary BRSV infection (Gaddum et al., 1996) . Previous studies have demonstrated the presence of BRSV-specific CTLs in the lung of calves 10 days after BRSV infection (Gaddum et al., 1996) . The failure to detect CTLs in the lungs of any of the BHV-1-vaccinated calves, 7 days after BRSV challenge in this study, suggests that BHV-1\G did not prime calves for a more rapid accumulation of BRSV-specific CTLs in the lung after challenge. Thus, the G protein does not appear to prime RSV-specific CTLs in calves, BALB\c mice (Alwan et al., 1993) or man, where the G protein was recognized by CTL from only two of nine previously infected individuals (Cherrie et al., 1992) . Although there was no evidence for priming of a BRSV-specific CTL response, there was priming of lymphocytes for a BRSV-specific proliferative response. The finding that the BRSV-specific proliferative response by lymphocytes from BHV-1\G-vaccinated calves was poor until 7 days after BRSV challenge is similar to that observed previously in calves vaccinated with rVV-G (Taylor et al., 1997) .
Scarification with rVV-G primes BALB\c, but not C57BL\6, mice for a pulmonary eosinophil influx 5 to 7 days after challenge with HRSV (Openshaw et al., 1992 ; Hussell et al., 1997) . A number of studies have shown that CD8 + T cells and IFN-γ play an important role in regulating pulmonary eosinophilia in mice primed with the G protein (Srikiatkhachorn & Braciale, 1997 ; Hussell et al., 1997) . Although vaccination with BHV-1\G did not appear to prime calves for RSV-specific CTL, it is possible that the absence of a pulmonary eosinophil influx in G-primed calves, 7 days after BRSV challenge, may be related to a dominance of IFN-γ in the lungs after BRSV infection. Preliminary studies indicate the presence of IFN-γ, IL-2 and IL-4 mRNA in the lungs of BRSV-infected calves (McInnes et al., 1998) and further studies are in progress to determine if vaccination alters the cytokine response to BRSV infection.
Previous studies have demonstrated that gE deletion mutants of BHV-1 are avirulent in calves Van Engelenburg et al., 1994) . Thus, i.n. infection of calves with wild-type BHV-1 results in fever, apathy, loss of appetite, lesions of the nasal mucosa and nasal discharge, whereas calves infected i.n. with gE-negative mutants of BHV-1 do not develop a fever or any other clinical signs except for small lesions of the nasal mucosa. Although, it was not possible to examine the nasal mucosae in this study, as calves were housed in plastic isolators, only mild clinical signs were observed even after i.n. and i.t. infection with BHV-1\gEfs. However, incorporation of the G protein of BRSV appeared to increase the virulence of BHV-1 for calves. The increased virulence of BHV-1\G compared with BHV-1\gEfs in gnotobiotic calves appeared to be associated with increased replication of BHV-1\G in the lungs. This observation is similar to that reported previously for mice inoculated i.n. with rVV expressing the G protein of HRSV. Thus, rVV-G replicated to higher titres in the lungs when compared with rVV expressing either the F or N proteins of HRSV (Taylor et al., 1991) . The reasons for the apparent replication advantage conferred by expression of the G protein of RSV are not clear. It may be that expression of the attachment protein of RSV facilitates infection of a greater number of respiratory mucosal cells. However, BHV-1\G appeared to grow to similar titres in the nasal mucosa as BHV-1\gEfs, indicating that expression of the G protein exerts a more pronounced effect in the lower respiratory tract than in the nasal passages. Therefore it may be that the G protein interferes with pulmonary defence mechanisms.
In conclusion, these results demonstrated that vaccination of calves with recombinant BHV-1 expressing the G protein of BRSV induced protection against BRSV infection in the lower and to a lesser extent also in the upper respiratory tract. Since previous studies have shown that prior infection with an avirulent gE-negative mutant of BHV-1 protects against disease induced by a virulent BHV-1 strain , these findings highlight the potential of BHV-1 as a bior even a multivalent vaccine against BHV-1 and other bovine pathogens. However, expression of the G protein by gEnegative BHV-1 increased the virulence of BHV-1 for the lower respiratory tract of calves. Therefore a recombinant BHV-1 expressing the F protein of BRSV may be a more suitable vaccine candidate, especially as the F protein induces neutralizing antibodies in the calf and is antigenically more conserved than the BRSV G protein (Taylor et al., 1997 ; Furze et al., 1997) . Since RNAs containing the authentic F gene sequence also appeared to be unstable in the nucleus of infected cells (Kuhnle et al., 1998) , modification of the F gene may be required for efficient expression by recombinant BHV-1.
